The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
When NCYT launched their COVID-19 assay on 31st January 2020 there had been 1 single case of COVID-19 reported in the entirety of the UK, I imagine a few thought that smacked of desperation then. We develop diagnostics for infectious diseases, I'd be more concerned if they weren't knocking up an assay.
The government cares, enough to buy a load of smallpox vaccine along with other european countries. Early onset symptoms are similar to STDs such as herpes, the difference being one is a lot more serious than the other if we wait for the more visibly striking and painful symptoms to manifest then it's too late the patient will have to deal with the full force of the disease. Missdiagnosis can have ramifications for both the patient and anyone they come into contact with.
The disease could simply burn itself out and be a short lived outbreak or it has the potential to fester away popping up in numbers around the world. Spain now has 54 confirmed/suspected cases, case numbers globally are now the highest of any recorded outbreak in very short order in atleast 13 countries.
It's not an end times plague (nor likely to be) but this is the raison d'etre of NCYT, we develop diagnostic tests for infectious diseases it's what we do and there is no commercially available monkeypox assay available that I know of, largely because there's never been infections seen in these numbers.
If you cannot see why NCYT and its shareholders would be interested in this situation then I cannot understand why you purport to be invested here.
The WHO are convening an emergency meeting about this outbreak in multiple countries. UK confirmed infections doubled this morning. Could be b@gger all to worry about but this is a disease that has historically struggled to transmit between humans and now we have community spread, albeit in low numbers right now.
An opportunity for the global first responders to bang out an assay? LFTs need not apply.
https://twitter.com/BNODesk/status/1527596155466657793?t=v7f7yHtd2vf-ahJ9hxXQ9Q&s=19
Welcome to the monkey pox tracker ;-)
https://t.co/698WJtm1Qk
This isn't going to end well, the very fact that they're willingly admitting it indicates things are bad there . Horrendous regime but that isn't the fault of the citizens. It was bad enough when the Wuhan strain ripped through completely unvaccinated populations with better health care provision.
https://t.co/3tWwuEz9tp
From allegedly one case to 18k in 24 hrs, it's not like the North Koreans to tell a pack of lies is it. Very little of their population vaccinated either, too late in any case to prevent this wave. I hope the leadership accept medical aid that they're going to desperately need, unlike the vaccines they turned down.
https://twitter.com/medriva/status/1524860151009886218?t=B8dipW2IBA4hD1mAb4H-cg&s=19
To be fair they're an r&d outfit who tried their hand at knocking out a covid test to capitalize on the pandemic so it wouldn't be fair to make that comparison . What some holders there need to be wary of is their cash burn, £21m last year and they only have £26m cab as of 31/12/2021 - assuming no reduction in outgoings this year they'll run out of money by April 2023 so a cash call will be inbound.
From the South African lab that broke omicron did the initial omicron analysis. Ba4 and Ba5 are likely going to bring a new wave in short order.
https://twitter.com/Tuliodna/status/1520123573192568832?t=18oZQxAKQqwxmC_Q6JZaRQ&s=19
I've watched a fair few IMC presentations from an array of companies since its launch, that's probably the best I've seen. Others can make of it what they will, there's a definite strategy - execution being the hard part.
The company seems determined to use CAB while the dispute is ongoing, they're appear confident that the outcome (when it occurs) will be positive imo.
In discussions with major corporates and seems a few products well along the development timeline so potential for news nearer term.
We seem very focussed on penetrating europe, probably where biosynex comes into play.
Just my opinion.
Valju, as a holder I don't want a repeat of the last 18 months tomorrow but this board has grasped every opportunity to disappoint us know that having very a heavy pi shareholding they're relatively safe from being held to account. I hope for better tomorrow and the CEO starts justifying his appointment but I won't be holding my breath.
Thursdays presentation will be more of the same, any questions critical or probing of the management will be ignored and frankly I'm bemused as to where they see the investment case is based on recent performance and communication. Even at these prices no institution has entertained taking a stake so they're left with PIs for whom they've shown nothing but contempt for in the last 18 months so who the hell are they trying to sell the story to?
I'm just hoping Biosynex provide a backstop for the share price and they recommence their accumulation, although selling does seem to be drying up with every sh@tty RNS that's released so there's that at least. What a sad state to be in, relying on a competitor to prop us up.
I find it unlikely the dispute will go all the way to court, the company have obviously (and possibly justifiably) dug their heels in over monies owed but does either party want the details of the circumstances surrounding the dispute making public. Both parties seem more than happy to be utilising the veil of the NDA to suit them, as already pointed out, if it goes to court the entirety of this sorry tale becomes a matter of public record. Guaranteed to embarrass someone. The best deals are when neither party is entirely satisfied.
Allmond has 5 months to somehow convince shareholders (90% of whom are PIs) ratify his appointment, based on his performance thus far, he's got his work cut out but that's just my opinion.
It's even more ironic considering the author of that article has actively lobbied for the removal of mitigations during the pandemic. Nevermind, the longer this goes on, the more replication space covid will get with the airlines providing a perfect conduit for its new variants delivery around the world.
I was aware that ONT had had their contract cancelled last April but wasn't aware that there'd been a dispute over outstanding invoices . Seems we weren't unique in the DHSCs attempt to screw over suppliers as they changed horses mid race for LFTs. Considering like ONT we've never been mentioned in terms of the GLP I don't think that's going to be an impediment to settlement. Besides, the GLPs case against the government would not be covered by the contractual NDA with the DHSC and the company would be obligated to notify us that settlement would be dependent on it's outcome .
I'd also like to see us pursue them for the inventory that we've had to write off. 30m would have sunk most companies of our size.
They've committed 4m of current cash to buyback 9m shares with the rest dependent on shareholders approval in May . They must be supremely confident of at least finding another 10m because as you say that is the minimum they will have to get together at the current mcap and I don't think their shareholders will be too happy if it's still languishing there afterwards so more will be needed. Sorry to go o/t.